National Abortion Federation’s 38th Annual Meeting: Standing Tall

April 5-8th, San Francisco

Gynuity staff presented on a number of topics at this meeting, including:
Medical abortion in the second trimester outside North America: Insights from Tunisia, Vietnam, Moldova and Armenia – Beverly Winikoff

Presentation at the Latin American Providers’ Meeting – Beverly Winikoff

Mifepristone-misoprostol for menstrual regulation in Bangladesh (poster) – Hillary Bracken

Medical abortion with mifepristone+misoprostol at 13-22 weeks: How long between the mifepristone and the misoprostol? (poster) – Dina Abbas

Acceptability of an outpatient regimen of medical abortion with mifepristone and 800mcg misoprostol administered buccally or sublingually at 71-84 days gestation: A series of exploratory studies – Dina Abbas

Panel session: Medical abortion service delivery improvements: Global evidence and updates on home-based client follow-up using sequential semi-quantitative urine pregnancy tests – Chair, Beverly Winikoff

Quantitative serum hCG testing pre and post procedure to confirm successful medical abortion is a recommended follow-up method by Planned Parenthood Federation of America and the World Health Organization. This panel presented data from new studies exploring the effectiveness, feasibility and acceptability of using sequential semi-quantitative urine pregnancy tests (SQPT) in lieu of serum hCG and/or transvaginal ultrasound to confirm successful medical abortion.

• Experiences of women in Mexico City using a semi-quantitative pregnancy test as medical abortion follow-up: Patricio Sanhueza, MD, Reproductive Health Coordinator, SSDF
• Streamlining medical abortion services in Tunisian public and private level facilities with semi-quantitative pregnancy tests at follow-up: Rasha Dabash, MPH, Gynuity
• Assessing successful early medical abortion 3, 7 and 14 days after mifepristone using a semi-quantitative pregnancy test: Can we shorten the medical abortion process?: Wendy Sheldon, PhD, MPH, Gynuity